Keypoints:
- Africa’s first public rollout of lenacapavir
- Twice-yearly jab cuts HIV risk by over ninety-nine percent
- High-burden nation prioritises rapid access
ESWATINI has unveiled a powerful new HIV-prevention injection, marking Africa’s first public rollout of the twice-yearly drug and signalling a major shift in the kingdom’s long-running battle against the virus. The Ministry of Health confirmed the development, which was first reported by both the Associated Press and AFP.
Officials described lenacapavir as a ‘transformative tool’ that could redefine prevention in one of the highest-burden nations on earth.
A heavy burden on a small nation
Eswatini, a country of roughly 1.2 million people, has about 220,000 residents living with HIV. The national prevalence rate has long been the highest in the world, prompting successive governments to prioritise prevention and invest in community health initiatives.
The introduction of lenacapavir is seen as a strategic leap forward. Health officials said the rollout follows months of planning, clinic preparation and coordination with global health partners to ensure the drug’s safe and equitable introduction.
A twice-yearly jab with major impact
Lenacapavir works by disrupting a key stage in the HIV replication cycle. Its long-acting formulation requires just two injections per year — a drastic simplification compared with daily PrEP pills. According to AP and AFP coverage, clinical data shows lenacapavir can reduce the risk of HIV transmission by more than ninety-nine percent when administered correctly.
Health workers say the simplified dosing schedule could transform prevention particularly for young people, rural communities and high-risk groups that struggle with regular clinic visits or adherence to daily medication.
Communities welcome new prevention option
Clinicians involved in the rollout told Africa Briefing that early interest from communities has been striking, with many residents viewing the injection as a discreet and manageable alternative to tablets. Community leaders and civil-society organisations have also voiced strong support, noting its potential to curb new infections among women and girls — groups disproportionately affected both in Eswatini and across Southern Africa.
The Ministry of Health has launched a nationwide awareness campaign explaining who qualifies for the jab, how follow-up visits will work, and why long-acting prevention is a safe and effective option.
Regional ripple effects expected
The launch has already drawn attention from health officials in neighbouring countries, who are monitoring uptake and community response. Analysts say Eswatini’s model could influence regional prevention strategies if the programme proves successful.
For now, Eswatini is focused on scaling supply, training health personnel, and ensuring that rural areas are not left behind. Authorities say early implementation data will be released in the coming months, offering the first indication of the programme’s wider public-health impact.
